TEM7 Antibody is affinity chromatography purified via peptide column.
Immunogène
TEM7 antibody was raised against a 16 amino acid synthetic peptide from near the center of human TEM7. The immunogen is located within amino acids 250 - 300 of TEM7.
PLXDC1
Reactivité: Humain
WB, IF, FACS
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
TEM7 antibody can be used for detection of TEM7 by Western blot at 0.5 - 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in rat samples, Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
TEM7 Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
TEM7 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
TEM7 Antibody: Tumor endothelial marker 7 (TEM7) was identified through serial analysis of gene expression on endothelial cells isolated from human normal and malignant colorectal tissues. Further experiments verified TEM7 was highly expressed in the endothelium of numerous other cancer types including breast, lung and brain tumors. At least four isoforms of TEM7 are known to exist, these include intracellular, secreted, and membrane-bound forms. A homologous protein, TEM7R (also known as PLXDC2), acts as a binding partner to TEM7 and is also abundantly expressed in the endothelium of malignant colorectal cancer but is absent or rare in normal colon mucosa. High expression of TEM7 is associated with metastasis and poor survival of patients with osteogenic sarcoma.